Moleculin Biotech
MBRX
22 hedge funds and large institutions have $3.17M invested in Moleculin Biotech in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
0% more capital invested
Capital invested by funds: $3.16M → $3.17M (+$11.1K)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
8% less funds holding
Funds holding: 24 → 22 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$41.4K |
| 2 |
VF
Virtu Financial
New York
|
+$15.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.38K |
| 4 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$844 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$844 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$21K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$12K |
| 3 |
BlackRock
New York
|
-$6.75K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.07K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Envestnet Asset Management
Chicago,
Illinois
| – | -$12K | -29 | Closed |
|
|
AIP
27
Almanack Investment Partners
Wayne,
Pennsylvania
| – | -$1K | -3 | Closed |
|
MBRX Hedge Fund Activity: Q4 2022 in Review
22 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2022, worth a combined $3.17M — up 0.35% from $3.16M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MBRX and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Charles Schwab, opening a new position worth an estimated $41.4K. The largest seller was Jane Street, exiting entirely with an estimated $21K sold.
- 22 institutional investors held Moleculin Biotech (MBRX) as of Q4 2022, down from 24 in Q3 2022.
- Funds reported $3.17M of Moleculin Biotech stock for Q4 2022, up 0.35% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q4 2022 and 4 closed out, a net change of -1 holder.
- The largest Moleculin Biotech buyer in Q4 2022 was Charles Schwab, an estimated $41.4K added.
- The largest Moleculin Biotech seller in Q4 2022 was Jane Street, an estimated $21K sold.
Based on aggregated 13F filings for Q4 2022.